64,996 Merck & Co., Inc. $MRK Shares Sold by Sumitomo Mitsui DS Asset Management Company Ltd

Sumitomo Mitsui DS Asset Management Company Ltd reduced its stake in shares of Merck & Co., Inc. (NYSE:MRK) by 9.4% during the 3rd quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 629,819 shares of the company’s stock after selling 64,996 shares during the period. Sumitomo Mitsui DS Asset Management Company Ltd’s holdings in Merck & Co., Inc. were worth $91,519,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also made changes to their positions in the company. Horizons Wealth Management purchased a new position in shares of Merck & Co., Inc. in the 3rd quarter valued at about $30,000. Bullseye Investment Management LLC acquired a new stake in shares of Merck & Co., Inc. in the second quarter valued at about $27,000. Graney & King LLC boosted its holdings in Merck & Co., Inc. by 400.0% during the second quarter. Graney & King LLC now owns 250 shares of the company’s stock worth $32,000 after buying an additional 200 shares in the last quarter. Montgomery Financial Services LLC purchased a new stake in Merck & Co., Inc. during the second quarter worth about $41,000. Finally, Evergreen Advisors LLC purchased a new stake in Merck & Co., Inc. during the first quarter worth about $43,000. 76.07% of the stock is owned by institutional investors and hedge funds.

Merck & Co., Inc. Stock Down 1.6%

Merck & Co., Inc. stock opened at $143.58 on Tuesday. Merck & Co., Inc. has a fifty-two week low of $82.01 and a fifty-two week high of $156.92. The firm has a market capitalization of $354.24 billion, a price-to-earnings ratio of 114.86, a price-to-earnings-growth ratio of 6.74 and a beta of 0.21. The stock’s fifty day moving average is $145.86 and its two-hundred day moving average is $129.48. The company has a debt-to-equity ratio of 1.22, a quick ratio of 1.10 and a current ratio of 1.32.

Merck & Co., Inc. (NYSE:MRK) last released its quarterly earnings results on Tuesday, August 4th. The company reported ($0.13) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.26) by $0.13. The business had revenue of $16.61 billion during the quarter, compared to the consensus estimate of $16.37 billion. Merck & Co., Inc. had a return on equity of 16.73% and a net margin of 4.77%. The business’s revenue was up 5.1% on a year-over-year basis. During the same quarter in the previous year, the company posted $2.13 EPS. Merck & Co., Inc. has set its FY 2026 guidance at 2.660-2.760 EPS. Analysts predict that Merck & Co., Inc. will post 2.66 EPS for the current fiscal year.

Merck & Co., Inc. Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Wednesday, October 7th. Investors of record on Tuesday, September 15th were paid a $0.85 dividend. This represents a $3.40 dividend on an annualized basis and a yield of 2.4%. The ex-dividend date of this dividend was Tuesday, September 15th. Merck & Co., Inc.’s dividend payout ratio is presently 272.00%.

Key Stories Impacting Merck & Co., Inc.

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Investors are evaluating Merck & Co.’s Phase 3 melanoma results, which could influence expectations for the company’s oncology pipeline and future growth beyond Keytruda. The market’s reaction will depend on the trial’s efficacy, safety and regulatory implications. How Investors Are Reacting To Merck Phase 3 Melanoma Results
• Neutral Sentiment: Analysts continue to view Merck’s dividend as an important part of the investment case, supported by its global pharmaceutical portfolio and Keytruda franchise. However, the income outlook is tied to the company’s ability to offset future Keytruda-related competitive and patent pressures. Merck’s 2.4% Dividend Yield: A Reliable Income Stream or a Risky Bet on Recovery?
• Neutral Sentiment: Merck is being discussed alongside other healthcare companies benefiting from artificial-intelligence-driven diagnostics, sequencing and drug development. The theme may support long-term sector interest, but the article does not identify a specific near-term catalyst for MRK. The AI Trade Just Moved Into Your Bloodstream, and 4 Healthcare Stocks Are Winning
• Negative Sentiment: Exchange-traded funds were net sellers of MRK on October 16, adding technical selling pressure and potentially contributing to weaker trading. ETFs Are Net Sellers of Merck on Oct. 16
• Negative Sentiment: Merck & Co. underperformed a stronger overall market in the latest session, reflecting investor caution despite its recent revenue growth and raised 2026 sales outlook. Merck Stock Dips While Market Gains
• Neutral Sentiment: Merck KGaA agreed to acquire Silence Therapeutics for $20 per American depositary share, a 130% premium. The deal drove SLN sharply higher but does not represent an acquisition by Merck & Co. (NYSE: MRK), so its direct impact on MRK is limited.

Insider Activity

In other Merck & Co., Inc. news, EVP David Williams sold 52,847 shares of the company’s stock in a transaction dated Wednesday, August 5th. The shares were sold at an average price of $128.77, for a total value of $6,805,108.19. Following the sale, the executive vice president owned 31,716 shares of the company’s stock, valued at $4,084,069.32. This represents a 62.49% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP David R. Maraldo sold 18,706 shares of the company’s stock in a transaction dated Wednesday, August 5th. The shares were sold at an average price of $128.72, for a total transaction of $2,407,836.32. Following the completion of the sale, the executive vice president directly owned 18,212 shares in the company, valued at $2,344,248.64. This trade represents a 50.67% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 228,238 shares of company stock worth $29,977,783 in the last three months. Company insiders own 0.17% of the company’s stock.

Analyst Ratings Changes

MRK has been the topic of several recent analyst reports. Royal Bank Of Canada lowered their target price on shares of Merck & Co., Inc. from $150.00 to $145.00 and set a “sector perform” rating on the stock in a research report on Monday, October 12th. Cantor Fitzgerald lifted their price target on shares of Merck & Co., Inc. from $120.00 to $145.00 and gave the company a “neutral” rating in a research report on Thursday, October 8th. JPMorgan Chase & Co. lifted their price target on shares of Merck & Co., Inc. from $150.00 to $165.00 and gave the company an “overweight” rating in a research report on Monday, October 5th. CICC Research assumed coverage on Merck & Co., Inc. in a research note on Wednesday, June 24th. They set an “outperform” rating and a $138.00 price target on the stock. Finally, Wall Street Zen cut Merck & Co., Inc. from a “buy” rating to a “hold” rating in a report on Saturday, October 3rd. Seventeen equities research analysts have rated the stock with a Buy rating and ten have issued a Hold rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $151.92.

Merck & Co., Inc. Company Profile

Merck & Co, Inc is a global healthcare company that develops, manufactures and markets prescription medicines, vaccines and animal-health products. Its pharmaceutical business focuses on oncology, infectious diseases, cardiology, immunology and other areas of significant medical need. The company serves patients, healthcare providers and institutions in markets worldwide.

Merck’s principal products include Keytruda, an immunotherapy used to treat a range of cancers; Gardasil and Gardasil 9, vaccines that help protect against human papillomavirus; and Januvia and Janumet, medicines used to manage type 2 diabetes.